Advertisement

Heparin-Induced Thrombocytopenia

  • Benilde CosmiEmail author
Chapter
  • 10 Downloads

Abstract

Unfractionated heparin (UFH) is the most commonly used anticoagulant during cardiac surgery. UFH can be easily monitored and its effect rapidly reversed by a low cost agent, protamine. However heparin use can be complicated by a rare and potentially fatal adverse immunological reaction namely heparin-induced thrombocytopenia (HIT). In HIT, heparin binds to platelet factor 4 (PF4), which is released by activated platelets. As a result, an immunological response can ensue with the development of IgG antibodies against heparin/PF4 complexes. The IgG/heparin/PF4 immune complexes activate platelets with intravascular platelet consumption resulting in thrombocytopenia and increased thrombin production with paradoxical, potentially life-threatening, thrombotic complications instead of bleeding. HIT diagnosis is based on the combination of pre-test clinical probability and the detection of platelet activating antibodies against heparin/PF4 complexes with immunological and functional assays. When HIT is confirmed, any form of heparin should be stopped and non-heparin alternative anticoagulants should be started. Only argatroban and danaparoid are currently licensed for HIT. Cardiac surgery should be delayed in patients with acute or sub-acute HIT until anti-heparin/PF4 antibodies are detectable. In case of urgent cardiac surgery or procedures, bivalirudin is an option, although no reversal agents are available. Other options are pre-operative therapeutic plasmapheresis or use of anti-platelet agents such as tirofiban, epoprostenol with UFH, albeit with increased risk of bleeding.

Keywords

Argatroban Anticoagulation Arterial thromboembolism Bivalirudin Danaparoid Direct oral anticoagulants ELISA Heparin Heparin-induced thrombocytopenia Platelet factor 4 Protamine Serotonin release assay Thrombocytopenia Thrombosis Venous thromboembolism 

Notes

Acknowledgment

Conflict of Interest Statement: The author declares to have received consulting fees and speakers fees from Daiichi Sankyo, Janssen in the last 5 years.

References

  1. 1.
    Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost. 2011;9(Suppl 1):105–17.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Ortel TL, Erkan D, Kitchens CS. How I treat catastrophic thrombotic syndromes. Blood. 2015;126:1285–93.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112:2607–16.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg. 1958;76:219–25.CrossRefGoogle Scholar
  5. 5.
    Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973;136:409–16.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Greinacher A, Delcea M. Another surprising finding in heparin-induced thrombocytopenia–eat big. J Thromb Haemost. 2015;13:1414–5.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373:252–61.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95–6.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res. 2008;122:211–20.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood. 2014;124:2442–9.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparininduced thrombocytopenia. Blood. 1994;84:3691–9.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl):e495S–530S.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Arepally G, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–17.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Zalcberg JR, McGrath K, Dauer R, Wiley JS. Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation [Letter]. Br J Haematol. 1983;54:655–7.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502–6.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Selleng S, Malowsky B, Itterman T, et al. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. Am Heart J. 2010;160:362–9.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Everett BM, Yeh R, Foo SY, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592–7.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Selleng S, Selleng K. Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients. Thromb Haemost. 2016;116:843–51.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159:528–40.PubMedGoogle Scholar
  20. 20.
    Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759–65.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120:4160–7.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Aouifi A, Blanc P, Piriou V, et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg. 2001;71:678–83.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Lillo-Le Louët LA, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost. 2004;2:1882–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Hicks LK, Bering H, Carson KR, et al. Five hematologic tests and treatments to question. Blood. 2014;124:3524–8.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Bakchoul T, Zöllner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol. 2014;36:296–305.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med. 2013;368:737–44.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106:3791–6.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Potzsch B, Klövekorn WP, Madlener K, et al. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343:515.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Warkentin TE, Anderson JAM. How I treat patients with a history of HIT. Blood. 2016;128:348–59.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Salter BS, Weiner MM, Trinh MA, et al. Heparin-induced thrombocytopenia. A comprehensive clinical review. J Am Coll Cardiol. 2016;67:2519–32.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83:572–7.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Antoniou T, Kapetanakis EI, Theodoraki K, et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum. 2002;5:354–7.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Koster A, Meyer O, Fischer T, et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg. 2001;122:1254–5.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg. 2010;110:30–5.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Warkentin TE, Sheppard JAI, Chu FV, et al. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood. 2015;125:195–8.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Voeller RK, Melby SJ, Grizzell BE, Moazami N. Novel use of plasmapheresis in a patient with heparin-induced thrombocytopenia requiring urgent insertion of a left ventricular assist device under cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2010;140:e56–8.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Lange P, Greif M, Bongiovanni D, et al. Bivalirudin vs heparin in patients who undergo transcatheter aortic valve Implantation. Can J Cardiol. 2015;31:998–1003.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Dangas GD, Lefèvre T, Kupatt C, et al. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol. 2015;66:2860–8.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Alsidawi S, Effat M. Peri-procedural management of anti-platelets and anticoagulation in patients undergoing MitraClip procedure. J Thromb Thrombolysis. 2014;38:416–9.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Toeg H, Ruel M, Haddad H, et al. Anticoagulation strategies for left ventricular assist devices. Curr Opin Cardiol. 2015;30:92–6.CrossRefGoogle Scholar
  42. 42.
    Koster A, Sänger S, Hansen R, et al. Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. ASAIO J. 2000;46:319–22.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Schenk S, El-Banayosy A, Prohaska W, et al. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. J Thorac Cardiovasc Surg. 2006;131:1373–1381.e4.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Warkentin TE, Greinacher A, Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann Thorac Surg. 2009;87:1633–40.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Koster A, Weng Y, Böttcher W, Gromann T, Kuppe H, Hetzer R. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg. 2007;83:1865–7.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Argueta-Morales IR, Olsen MC, DeCampli WM, et al. Alternative anticoagulation during cardiovascular procedures in pediatric patients with heparin-induced thrombocytopenia. J Extra Corpor Technol. 2012;44:69–74.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Linkins LA. Heparin induced thrombocytopenia. BMJ. 2015;350:g7566.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Shore-Lesserson L, Baker RA, Ferraris VA, et al. The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines—anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2018;105:650–62.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Angiology and Blood CoagulationS. Orsola-Malpighi University HospitalBolognaItaly

Personalised recommendations